Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
Trial Summary
What is the purpose of this trial?
This trial is testing VX-548, a new medication, to see if it can help reduce pain in patients who have had abdominoplasty surgery. VX-548 likely works by blocking pain signals in the body.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VX-548, HB/APAP, or placebo for acute pain management after abdominoplasty
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- HB/APAP
- Placebo (matched to HB/APAP)
- Placebo (matched to VX-548)
- VX-548
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vertex Pharmaceuticals Incorporated
Lead Sponsor
Dr. David Altshuler
Vertex Pharmaceuticals Incorporated
Chief Medical Officer since 2020
MD, PhD
Dr. Reshma Kewalramani
Vertex Pharmaceuticals Incorporated
Chief Executive Officer since 2020
MD, trained in internal medicine and nephrology